<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696628</url>
  </required_header>
  <id_info>
    <org_study_id>9806</org_study_id>
    <secondary_id>2017-A01589-44</secondary_id>
    <nct_id>NCT03696628</nct_id>
  </id_info>
  <brief_title>Modeling and Pharmacological Targeting of Genetic Cardiomyopathy in Children Via Cardiomyocytes Derived From Induced Pluripotent Stem Cells (DMDstem)</brief_title>
  <acronym>DMDstem</acronym>
  <official_title>Modeling and Pharmacological Targeting of Genetic Cardiomyopathy in Children Via Cardiomyocytes Derived From Induced Pluripotent Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional, cross-sectional biomedical study of children with genetic cardiomyopathy and&#xD;
      healthy children. The aim is to generate, via induced human pluripotent stem cells (hiPSC),&#xD;
      &quot;patient-specific&quot; cardiomyocytes (CMs) (hiPSC-CMs) to study the molecular mechanisms of&#xD;
      cardiomyopathies of genetic origin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional, cross-sectional biomedical study of children with genetic cardiomyopathy and&#xD;
      healthy children. The aim is to generate, via induced human pluripotent stem cells (hiPSC),&#xD;
      &quot;patient-specific&quot; cardiomyocytes (CMs) (hiPSC-CMs) to study the molecular mechanisms of&#xD;
      cardiomyopathies of genetic origin.&#xD;
&#xD;
      The study will be proposed to the parents or legal guardians of the children from 0 to 17&#xD;
      included sent in pediatric cardiology consultation to the University Hospital of Montpellier&#xD;
      as part of their usual follow-up or a health check (control) .&#xD;
&#xD;
      The only direct intervention performed on the patient is a venous blood sample. The volume of&#xD;
      blood collected will be lower than the thresholds defined in the Decree of December 2nd, 2016&#xD;
      on minimal risks in biomedical research (3 ml).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants receive the same intervention throughout the protocol, no matter if they are &quot;healthy children&quot; or &quot;cardiomyopathic children&quot;.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open : no masking us used. All involved know the identity of the intervention assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>hiPSC-cardiomyocytes culture</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>Blood test with generated hiPSC-cardiomyocytes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cardiomyopathy, Familial</condition>
  <arm_group>
    <arm_group_label>Healthy children</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiomyopathic children</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrocardiogram</intervention_name>
    <description>heart testing</description>
    <arm_group_label>Cardiomyopathic children</arm_group_label>
    <arm_group_label>Healthy children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>physical examination</intervention_name>
    <description>done by the investigator</description>
    <arm_group_label>Cardiomyopathic children</arm_group_label>
    <arm_group_label>Healthy children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>echocardiography</intervention_name>
    <description>heart testing</description>
    <arm_group_label>Cardiomyopathic children</arm_group_label>
    <arm_group_label>Healthy children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes</description>
    <arm_group_label>Cardiomyopathic children</arm_group_label>
    <arm_group_label>Healthy children</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1 : Child with genetic cardiomyopathy&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Child from 0 to 17 years old included&#xD;
&#xD;
          -  Bearer or at risk of cardiomyopathy of genetic origin. Written and informed consent of&#xD;
             parents or guardians of legal guardians&#xD;
&#xD;
          -  Affiliation or beneficiary of a social security scheme&#xD;
&#xD;
        Criterion of non-inclusion&#xD;
&#xD;
        . Cardiomyopathy of non-genetic origin (metabolic, toxic, malformative, etc.)&#xD;
&#xD;
        Group 2 : Healthy child&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Children aged 0 to 17 years old&#xD;
&#xD;
          -  Normal assessment: clinical examination, ECG, echocardiography&#xD;
&#xD;
          -  Written and informed consent&#xD;
&#xD;
          -  Affiliation or beneficiary of a social security scheme&#xD;
&#xD;
        Criterion of non-inclusion&#xD;
&#xD;
          -  Heart, muscle or respiratory disease&#xD;
&#xD;
          -  Treatment with cardiac resonance&#xD;
&#xD;
          -  Other chronic diseases (diabetes, neuropathy, kidney failure, tumor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pascal AMEDRO, PhD</last_name>
    <phone>+33 (0) 4 67 33 66 39</phone>
    <email>p-amedro@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal AMEDRO, PhD</last_name>
      <phone>+33 (0) 4 67 33 66 39</phone>
      <email>p-amedro@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Souidi M, Amédro P, Meyer P, Desprat R, Lemaître JM, Rivier F, Lacampagne A, Meli AC. Generation of three Duchenne Muscular Dystrophy patient-specific induced pluripotent stem cell lines DMD_YoTaz_PhyMedEXp, DMD_RaPer_PhyMedEXp, DMD_OuMen_PhyMedEXp (INSRMi008-A, INSRMi009-A and INSRMi010-A). Stem Cell Res. 2020 Dec;49:102094. doi: 10.1016/j.scr.2020.102094. Epub 2020 Nov 19.</citation>
    <PMID>33246213</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiomyocytes</keyword>
  <keyword>Induced pluripotent stem cells</keyword>
  <keyword>Genetic cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

